Patients with BAT Visualization on One or More Studies
| SUV* | Associated PET/CT study† | |||||||
|---|---|---|---|---|---|---|---|---|
| Patient no. | Age (y) | Sex | 18F-FDG PET/CT | 18F-F-DA PET/CT | 123I-MIBG SPECT | Final diagnosis | Plasma norepinephrine (pg/mL) | Plasma epinephrine (pg/mL) |
| 1 | 48 | F | N | NA | P | Pheo | 1,712, 18F-F-DA | |
| 2 | 17 | M | NA | P (4.3) | NA | Not pheo | 351, 18F-F-DA | 72, 18F-F-DA |
| 3 | 40 | M | P (3.8) | NA | NA | Pheo | 2,791, 18F-FDG | 24, 18F-FDG |
| 2,791, 18F-F-DA | 24, 18F-F-DA | |||||||
| 4 | 25 | F | P (2.4) | N | NA | Pheo | 2,569, 18F-F-DA | |
| 5 | 32 | F | N | NA | P | Pheo | NA | NA |
| 6 | 56 | F | N | N | P | Not pheo | 400, 18F-FDG | 18, 18F-FDG |
| 400, 18F-F-DA | 18, 18F-F-DA | |||||||
| 7 | 39 | F | P (4.1) | N | N | Pheo | 767, 18F-F-DA | NA |
| 8 | 29 | M | P (1.4) | N | P | Pheo | 27,456, 18F-FDG | 15, 18F-FDG |
| 27,456, 18F-F-DA | 15, 18F-F-DA | |||||||
| 9 | 26 | F | P (9.0) | NA | N | Pheo | 141,299, 18F-FDG | 129, 18F-FDG |
| 10 | 27 | F | NA | P (3.4) | NA | Pheo | 496, 18F-F-DA | 7, 18F-F-DA |
| 11 | 38 | F | P (1.6) | NA | NA | Pheo | 1,510, 18F-F-DA | 40, 18F-F-DA |
| 12 | 38 | F | N | P (2.1) | NA | Not pheo | 225, 18F-FDG | 34, 18F-FDG |
| 225, 18F-F-DA | 34, 18F-F-DA | |||||||
| 13 | 49 | F | P (2.0) | NA | NA | Not pheo | 1,301, 18F-FDG | 16, 18F-FDG |
| 14 | 34 | M | N | P (4.4) | N | Pheo | 549, 18F-FDG | 59, 18F-FDG |
| 549, 18F-F-DA | 59, 18F-F-DA | |||||||
| 15a‡ | 30 | M | P (3.2) | P (1.5) | N | Pheo | 31,429, 18F-F-DA | 86, 18F-F-DA |
| 15b‡ | 29 | M | P (17.7) | NA | NA | Pheo | NA | NA |
| 16§ | 29 | M | N§ | P (3.0)§ | P§ | Pheo | 261, 18F-F-DA | 38, 18F-F-DA |
| 17a‡ | 26 | F | NA | P (3.6) | NA | Previous pheo | 210, 18F-F-DA | 18, 18F-F-DA |
| 17b‡ | 26 | F | P (5.0) | NA | P | Previous pheo | 278, 18F-FDG | 7, 18F-FDG |
| 18 | 24 | F | P (8.0) | P (2.0) | NA | Pheo | 598, 18F-F-DA | 4, 18F-F-DA |
| 19 | 66 | F | P (1.6) | NA | NA | Pheo | 22,587, 18F-FDG | 64, 18F-FDG |
| 20 | 33 | M | P (5.4) | NA | P | Pheo | 895, 18F-F-DA | NA |
| 21 | 17 | F | N | P (2.0) | P | Not pheo | 1,093, 18F-FDG | 26, 18F-FDG |
| 1,093, 18F-F-DA | 26, 18F-F-DA | |||||||
| 22 | 38 | F | P (3.5) | NA | P | Not pheo | 349, 18F-FDG | 19, 18F-FDG |
| 23a‡ | 28 | M | P (5.0) | NA | P | Pheo | NA | NA |
| 23b‡ | 28 | M | P (1.8) | NA | Pheo | NA | NA | |
| 24 | 13 | M | P (4.6) | P (4.8) | P | Pheo | 3,407, 18F-F-DA | 10, 18F-F-DA |
| 25 | 19 | F | N | P (2.0) | N | Neuroblastoma | 888, 18F-FDG | NA |
| 888, 18F-F-DA | ||||||||
| 26 | 22 | M | P (1.0) | N | N | Pheo | 1,811, 18F-FDG | 3, 18F-FDG |
| 1,811, 18F-F-DA | 3, 18F-F-DA | |||||||
| Positive findings | 17 (16) | 12 | 11 | |||||
↵* SUV is reported only for BAT+. Findings: P = positive for BAT; N = negative for BAT; NA = data not available.
↵† Plasma catecholamine was measured within 0–3 d of corresponding PET/CT study. In some cases, both PET/CT studies were within 3 d of laboratory measurement.
↵‡ Same patient with 1 positive result on different modalities several months apart (on different modalities or contemporaneous with different modalities).
↵§ Chronologic order of studies in this patient was first 18F-F-DA, then 123I-MIBG, and finally 18F-FDG. 18F-FDG study was not contemporaneous (41 d) with 18F-F-DA but was contemporaneous with 123I-MIBG; 18F-F-DA and 123I-MIBG studies were contemporaneous.
Pheo = pheochromocytoma.